Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 228

1.

Plasma enterolactone and genistein and the risk of premenopausal breast cancer.

Piller R, Chang-Claude J, Linseisen J.

Eur J Cancer Prev. 2006 Jun;15(3):225-32.

PMID:
16679865
2.

Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland.

Pietinen P, Stumpf K, Männistö S, Kataja V, Uusitupa M, Adlercreutz H.

Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):339-44.

3.

CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans.

Piller R, Verla-Tebit E, Wang-Gohrke S, Linseisen J, Chang-Claude J.

J Nutr. 2006 Jun;136(6):1596-603.

PMID:
16702327
4.

An incident case-referent study on plasma enterolactone and breast cancer risk.

Hultén K, Winkvist A, Lenner P, Johansson R, Adlercreutz H, Hallmans G.

Eur J Nutr. 2002 Aug;41(4):168-76.

PMID:
12242585
5.

Urinary phytoestrogens and postmenopausal breast cancer risk.

den Tonkelaar I, Keinan-Boker L, Veer PV, Arts CJ, Adlercreutz H, Thijssen JH, Peeters PH.

Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):223-8.

6.

Comparison of plasma and urinary phytoestrogens in Japanese and Finnish women by time-resolved fluoroimmunoassay.

Uehar M, Arai Y, Watanabe S, Adlercreutz H.

Biofactors. 2000;12(1-4):217-25.

PMID:
11216489
7.

Dietary phytoestrogen, serum enterolactone and risk of prostate cancer: the cancer prostate Sweden study (Sweden).

Hedelin M, Klint A, Chang ET, Bellocco R, Johansson JE, Andersson SO, Heinonen SM, Adlercreutz H, Adami HO, Grönberg H, Bälter KA.

Cancer Causes Control. 2006 Mar;17(2):169-80.

PMID:
16425095
8.

Plasma enterolactone and breast cancer risk in the Nurses' Health Study II.

Xie J, Tworoger SS, Franke AA, Terry KL, Rice MS, Rosner BA, Willett WC, Hankinson SE, Eliassen AH.

Breast Cancer Res Treat. 2013 Jun;139(3):801-9. doi: 10.1007/s10549-013-2586-y. Epub 2013 Jun 13.

9.

Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group.

Iwasaki M, Inoue M, Otani T, Sasazuki S, Kurahashi N, Miura T, Yamamoto S, Tsugane S; Japan Public Health Center-based prospective study group.

J Clin Oncol. 2008 Apr 1;26(10):1677-83. doi: 10.1200/JCO.2007.13.9964. Epub 2008 Mar 3.

PMID:
18316793
10.

Plasma enterolactone and breast cancer incidence by estrogen receptor status.

Olsen A, Knudsen KE, Thomsen BL, Loft S, Stripp C, Overvad K, Møller S, Tjønneland A.

Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2084-9.

11.

Reliability of serum measurements of lignans and isoflavonoid phytoestrogens over a two-year period.

Zeleniuch-Jacquotte A, Adlercreutz H, Akhmedkhanov A, Toniolo P.

Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):885-9.

12.

Enterolactone as a risk factor for breast cancer: a review of the published evidence.

Boccardo F, Puntoni M, Guglielmini P, Rubagotti A.

Clin Chim Acta. 2006 Mar;365(1-2):58-67. Epub 2005 Sep 15. Review.

PMID:
16168401
13.

Phytoestrogens and breast cancer risk. Review of the epidemiological evidence.

Peeters PH, Keinan-Boker L, van der Schouw YT, Grobbee DE.

Breast Cancer Res Treat. 2003 Jan;77(2):171-83. Review.

PMID:
12602916
14.

The protective association of high plasma enterolactone with breast cancer is reasonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes.

Sonestedt E, Ivarsson MI, Harlid S, Ericson U, Gullberg B, Carlson J, Olsson H, Adlercreutz H, Wirfält E.

J Nutr. 2009 May;139(5):993-1001. doi: 10.3945/jn.108.101691. Epub 2009 Mar 25.

PMID:
19321582
15.

Enterolactone is differently associated with estrogen receptor beta-negative and -positive breast cancer in a Swedish nested case-control study.

Sonestedt E, Borgquist S, Ericson U, Gullberg B, Olsson H, Adlercreutz H, Landberg G, Wirfält E.

Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3241-51. doi: 10.1158/1055-9965.EPI-08-0393.

16.

Urinary excretion of phytoestrogens and risk of breast cancer among Chinese women in Shanghai.

Dai Q, Franke AA, Jin F, Shu XO, Hebert JR, Custer LJ, Cheng J, Gao YT, Zheng W.

Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):815-21.

17.

Changes in serum enterolactone, genistein, and daidzein in a dietary intervention study in Finland.

Stumpf K, Pietinen P, Puska P, Adlercreutz H.

Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1369-72.

18.

Serum enterolactone levels and the risk of breast cancer in women with palpable cysts.

Boccardo F, Lunardi G, Guglielmini P, Parodi M, Murialdo R, Schettini G, Rubagotti A.

Eur J Cancer. 2004 Jan;40(1):84-9.

PMID:
14687793
19.

Phyto-oestrogens and risk of prostate cancer in Scottish men.

Heald CL, Ritchie MR, Bolton-Smith C, Morton MS, Alexander FE.

Br J Nutr. 2007 Aug;98(2):388-96. Epub 2007 Apr 3.

PMID:
17403269
20.

Dietary phytoestrogen intake--lignans and isoflavones--and breast cancer risk (Canada).

Cotterchio M, Boucher BA, Kreiger N, Mills CA, Thompson LU.

Cancer Causes Control. 2008 Apr;19(3):259-72. Epub 2007 Nov 9.

PMID:
17992574

Supplemental Content

Support Center